TheraRadar
← Back
Data updated: Jun 28, 2026

ITALFARMACO SPA

Pharma
OncologyImmunologyGastroenterology Execution: Fair

ITALFARMACO SPA is a pharmaceutical company focused on Oncology, Immunology, Gastroenterology. Key products include DUVYZAT.

2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2024)
1 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 1 novel approval →
2024 DUVYZAT (GIVINOSTAT HYDROCHLORIDE) First-in-Class · Orphan · Priority Review · Fast Track

ITALFARMACO SPA at a Glance

  • Fast trial execution (21 months median completion)

ITALFARMACO SPA's Key Drugs

ITALFARMACO SPA's core commercial portfolio centers on DUVYZAT, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.

DUVYZAT
Rare Disease

Duchenne Muscular Dystrophy

Histone deacetylase Approved 2024

ITALFARMACO SPA's Recent FDA Approvals

New NDA/BLA approvals for ITALFARMACO SPA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ITALFARMACO SPA's Therapeutic Areas

ITALFARMACO SPA's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 70%
0 drugs Phase 2: 3 Phase 1: 1
Immunology 20%
0 drugs Phase 2: 1
Gastroenterology 10%
0 drugs Phase 1: 1

ITALFARMACO SPA's Top Competitors

ITALFARMACO SPA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Gastroenterology, Oncology
Pfizer big-pharma
Oncology, Immunology
PF PRISM CV big-pharma
Oncology, Immunology, Gastroenterology

ITALFARMACO SPA Pipeline Snapshot

ITALFARMACO SPA has 6 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 4 Phase 2 and 2 Phase 1.

0
Phase 3
4
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DUVYZAT leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/3 completed
  • • Speed: 21 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges